- 2023 - Successfully listed on the National Stock Exchange’s.
- 2022 - Incorporated subsidiary company in bio-fuel segment for backward integration.
- 2021 - Augmentation of production capacity and construction of new Premises.
- 2019 - Expanded reach to over 15+ countries across the globe.
- 2018 - Product Portfolio touched 200+ Iodine Derivatives and 7+ APIs.
- 2017 - Certified as WHO-GMP and ISO 14001-2015.
- 2015 - Received Indian FDA approval for manufacturing of APIs.
- 2014 - Upgraded Plant with GMP compliant large-scale manufacturing facility.
- 2011 - Penetrated the pharmaceutical market with CRAMS Model.